Actively Recruiting
Study of Pulmonary Suffusion with Cisplatin and Surgery for Lung Metastases from Sarcoma or Colorectal Cancer
Led by Roswell Park Cancer Institute · Updated on 2026-08-21
99
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the use of pulmonary suffusion, a minimally invasive method to deliver chemotherapy directly to the lungs, in patients with sarcoma or colorectal cancer that has spread to the lungs. The trial aims to evaluate the safety and effectiveness of this approach in controlling minimal residual disease after lung metastases have been removed or ablated. This trial includes both Phase I and Phase II portions, focusing on safety, local recurrence rates, and disease-free survival compared to historical controls. Participants receive pulmonary suffusion treatment using cisplatin, delivered by infusion directly to the lungs. After this, patients undergo surgery to remove lung metastases or ablation of lung nodules. Those with unresectable sarcoma may receive additional chemotherapy within 4 to 8 weeks after surgery. The study assesses the best dose for treatment and monitors side effects related to chemotherapy isolated to the lungs. During the study, participants will be closely monitored with follow-up visits for up to five years after treatment. Researchers will track local and systemic toxicities, rates of cancer recurrence in the lungs, disease-free survival, and overall survival. Various biomarkers and tumor tissue samples will be analyzed to understand treatment effects and immune responses. Follow-up includes regular clinical assessments and imaging to evaluate disease control and safety.
CONDITIONS
Brief Title
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
Research Team
K
Kenneth Seastedt
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here